Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remdesivir and Baricitinib Combination Therapy for COVID-19 ARDS
NCT04693026Phase 3Unknown
- Sponsor
- M Abdur Rahim Medical College and Hospital
- Start
- Sep 2020
- Primary completion
- Feb 2021
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of baricitinib in COVID-19-associated acute respiratory distress syndrome (CARDS), sponsored by M Abdur Rahim Medical College and Hospital. Status: unknown.
02
Drugs
baricitinib
03
Conditions
COVID-19-associated acute respiratory distress syndrome (CARDS)
Beyond the preview
Go deeper on NCT04693026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04693026.